PHILADELPHIA--(BUSINESS WIRE)--Aro Biotherapeutics, a biotechnology company pioneering the development of tissue-targeted genetic medicines, today announced upcoming data presentations highlighting ...
FUJIFILM Corporation announces the successful validation of the cancer cell-targeting potential of its peptide-oligonucleotide conjugates. This validation resulted from combining oligonucleotides with ...
AstraZeneca has extended its drug delivery collaboration with Aptamer Group. The revised deal sets AstraZeneca up to build on research into the use of aptamer molecules to target renal cells. In 2019, ...
ProteinQure announced new preclinical results today, demonstrating efficient delivery of small interfering RNA (siRNA) to the central nervous system (CNS) in non-human primates. Using intrathecal ...
Avidity Biosciences excels in antibody oligonucleotide conjugates, with its stock tripling in the past year due to innovative clinical advancements. Lead asset AOC1001 shows promising results in ...
Preclinical data shows use of megalin receptors for intracellular delivery of a ligand-siRNA conjugate to silence production of target mRNA in the kidney Megalin-binding genetic medicines are ...
LA JOLLA, Calif., Nov. 4, 2021 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody ...
Delpacibart etedesiran led mostly to mild to moderate adverse events in a phase I/II trial of myotonic dystrophy type 1, but two serious events occurred. The antibody-oligonucleotide conjugate reduced ...
Avidity Biosciences, Inc. (RNA) is an early stage biopharma with a multi-billion dollar valuation. These types of companies always interest me. On the one hand, due to their early stages, they appear ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results